MARK BRYAN TING: Open Payments
NPI 1588925861 · FRESNO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,849 in 67 payments from 11 companies in 2025. Trend: 2023 $715 · 2024 $1,132 · 2025 $1,849
Food & beverage: $1,658Education: $191
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 18 | $427 |
| Alkermes, Inc. | 11 | $326 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $252 |
| Janssen Pharmaceuticals, Inc | 9 | $211 |
| Teva Pharmaceuticals USA, Inc. | 3 | $200 |
| E.R. Squibb & Sons, L.L.C. | 6 | $174 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $98 |
| ABBVIE INC. | 3 | $81 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Neurocrine BioSciences, Inc. | 1 | $28 |
Products named: FANAPT, CAPLYTA, ARISTADA, INVEGA SUSTENNA, COBENFY, LYBALVI, JOURNAVX, VRAYLAR.
Industry payments across CA — which companies pay providers there.
